Impact of the MIC of Piperacillin-Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum-B-Lactamase- Producing Escherichia coli

2016-03-292016-03-292013-070066-4804http://hdl.handle.net/11441/39080We investigated the impact of the piperacillin-tazobactam MIC in the outcome of 39 bloodstream infections due to extended- spectrum-B-lactamase-producing Escherichia coli. All 11 patients with urinary tract infections survived, irrespective of the MIC. For other sources, 30-day mortality was lower for isolates with a MIC of <2 mg/liter than for isolates with a higher MIC (0% ver- sus 41.1%; P = 0.02)application/pdfengAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/AntibacterianosEstudios de cohortesQuimioterapia combinadaInfecciones por escherichia coliPruebas de sensibilidad microbianaÁcido senicilánicoInfecciones urinariasImpact of the MIC of Piperacillin-Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum-B-Lactamase- Producing Escherichia coliinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccesshttp://dx.doi.org/10.1128/AAC.00135-13https://idus.us.es/xmlui/handle/11441/39080